NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, Price Target & More

Get Started

$89.36 +0.74 (+0.84 %)

(As of 05/27/2018 03:36 PM ET)

Previous Close$89.36

Today's Range$88.2450 - $89.87

52-Week Range$45.96 - $92.18

Volume145,561 shs

Average Volume322,499 shs

Market Capitalization$5.15 billion

P/E Ratio-13.24

Dividend YieldN/A

Beta1.98

About Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:AGIO

CUSIPN/A

Webwww.agios.com

Phone617-649-8600

Debt

Debt-to-Equity RatioN/A

Current Ratio10.75

Quick Ratio10.75

Price-To-Earnings

Trailing P/E Ratio-13.24

Forward P/E Ratio-13.73

P/E GrowthN/A

Sales & Book Value

Annual Sales$43.01 million

Price / Sales119.69

Cash FlowN/A

Price / CashN/A

Book Value$15.03 per share

Price / Book5.95

Profitability

EPS (Most Recent Fiscal Year)($6.75)

Net Income$-314,670,000.00

Net Margins-822.32%

Return on Equity-61.70%

Return on Assets-43.75%

Miscellaneous

Employees382

Outstanding Shares57,610,000

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals Inc (NASDAQ:AGIO) posted its quarterly earnings results on Friday, May, 4th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by $0.03. The biopharmaceutical company had revenue of $8.80 million for the quarter, compared to analysts' expectations of $11.93 million. Agios Pharmaceuticals had a negative return on equity of 61.70% and a negative net margin of 822.32%. The company's revenue for the quarter was down 16.2% on a year-over-year basis. During the same period in the prior year, the company earned ($1.56) earnings per share. View Agios Pharmaceuticals' Earnings History.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Agios Pharmaceuticals.

What price target have analysts set for AGIO?

12 analysts have issued twelve-month target prices for Agios Pharmaceuticals' stock. Their forecasts range from $75.00 to $117.00. On average, they expect Agios Pharmaceuticals' stock price to reach $91.70 in the next twelve months. View Analyst Ratings for Agios Pharmaceuticals.

What are Wall Street analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:

1. Cann analysts commented, "While we have not modeled any revenue impact from AG-270 to either Agios or Celgene by 2022, we believe that AG-270 could be an important value driver for Agios and Celgene. AG-270 is a novel compound in the field of synthetic lethality, and has the potential to address large patient populations. We are not making any changes to our outlook at this time, but we continue to watch the timing of the program closely." (4/17/2018)
2. According to Zacks Investment Research, "Agios received an FDA approval of Idhifa (enasidenib) in August for treatment of AML, which was a huge boost, given the immense commercial potential in the target market. We are also optimistic about its collaboration with Celgene as it provides Agios with regular funds. The company’s progress with the pipeline candidates, AG-120 and AG-881, has been quite impressive too. In December, the company submitted a new drug application to the FDA for AG-120 for treatment of AML. Shares of the company have outperformed the industry in the last one year. However, Agios depends heavily on partner Celgene for revenues as Idhifa is only in the early stages of launch. Also, the decision to discontinue the development of AG-519 was disappointing. Stiff competition is another matter of concern for the company." (1/16/2018)

Who are some of Agios Pharmaceuticals' key competitors?

Some companies that are related to Agios Pharmaceuticals include Mylan (MYL), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Merck Group (MKGAF), Genmab (GNMSF), Perrigo (PRGO), BeiGene (BGNE), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE) and Alkermes (ALKS).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:

Dr. David P. Schenkein, CEO, Pres & Director (Age 61)
Dr. Lewis Clayton Cantley, Co-Founder & Member of Scientific Advisory Board (Age 69)
Mr. Andrew Hirsch, Chief Financial Officer (Age 47)
Dr. Scott A. Biller Ph.D., Chief Scientific Officer (Age 62)
Dr. Christopher J. Bowden, Chief Medical Officer (Age 57)

Has Agios Pharmaceuticals been receiving favorable news coverage?

News headlines about AGIO stock have trended somewhat negative on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Agios Pharmaceuticals earned a media sentiment score of -0.02 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 47.35 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.57%), BB Biotech AG (4.40%), Lord Abbett & CO. LLC (1.81%), Alkeon Capital Management LLC (1.16%), Baillie Gifford & Co. (1.01%) and Point72 Asset Management L.P. (0.70%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Celgene European Investment Co, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, Kaye I Foster-Cheek, Lewis Clayton Jr Cantley, Robert Nelsen, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

Which institutional investors are selling Agios Pharmaceuticals stock?

AGIO stock was sold by a variety of institutional investors in the last quarter, including BB Biotech AG, Legal & General Group Plc, Royal Bank of Canada, Eventide Asset Management LLC, A.R.T. Advisors LLC, Opus Point Partners Management LLC, Eaton Vance Management and Loomis Sayles & Co. L P. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, David P Schenkein, Kaye I Foster-Cheek, Lewis Clayton Jr Cantley, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals.

Which institutional investors are buying Agios Pharmaceuticals stock?

AGIO stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Baillie Gifford & Co., BlackRock Inc., Point72 Asset Management L.P., Neuberger Berman Group LLC, Alkeon Capital Management LLC, Frontier Capital Management Co. LLC and Dimensional Fund Advisors LP. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Celgene European Investment Co, Corp /De/ Celgene and David Scadden. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $89.36.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $5.15 billion and generates $43.01 million in revenue each year. The biopharmaceutical company earns $-314,670,000.00 in net income (profit) each year or ($6.75) on an earnings per share basis. Agios Pharmaceuticals employs 382 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]

MarketBeat Community Rating for Agios Pharmaceuticals (AGIO)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		274 (Vote Outperform)
Underperform Votes:		254 (Vote Underperform)
Total Votes:		528

MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe AGIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Agios Pharmaceuticals (NASDAQ:AGIO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

12 Wall Street analysts have issued ratings and price targets for Agios Pharmaceuticals in the last 12 months. Their average twelve-month price target is $91.70, suggesting that the stock has a possible upside of 2.62%. The high price target for AGIO is $117.00 and the low price target for AGIO is $75.00. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.67	2.64	2.73	2.92
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$91.70	$87.3333	$85.6667	$75.70
Price Target Upside:	2.62% upside	1.53% upside	9.87% upside	26.93% upside

Agios Pharmaceuticals (NASDAQ:AGIO) Consensus Price Target History

Price Target History for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/23/2018	Citigroup	Initiated Coverage	Buy	$117.00	High
5/7/2018	Credit Suisse Group	Set Price Target	Buy	$95.00	Low
5/7/2018	SunTrust Banks	Set Price Target	Buy ➝ Buy	$115.00	Medium
4/17/2018	Cann	Reiterated Rating	Hold		Low
2/15/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$76.00 ➝ $85.00	Low
2/15/2018	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$72.00 ➝ $86.00	Low
2/14/2018	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Low
2/14/2018	UBS	Downgrade	Outperform ➝ Market Perform		Low
1/18/2018	Royal Bank of Canada	Boost Price Target	Outperform	$91.00	Medium
12/12/2017	Canaccord Genuity	Set Price Target	Buy	$90.00	High
8/2/2017	Leerink Swann	Upgrade	Market Perform ➝ Outperform	$50.00 ➝ $80.00	High
8/1/2017	Janney Montgomery Scott	Reiterated Rating	Hold		High
2/16/2017	Cowen	Reiterated Rating	Buy		N/A
1/17/2017	CIBC	Upgrade	Market Perform ➝ Outperform		N/A
8/19/2016	BTIG Research	Initiated Coverage	Neutral		N/A
8/10/2016	Goldman Sachs Group	Reiterated Rating	Neutral	$46.00	N/A

(Data available from 5/27/2016 forward)

Agios Pharmaceuticals (NASDAQ:AGIO) Earnings History and Estimates Chart

Earnings by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) Earnings Estimates

2018 EPS Consensus Estimate: ($6.31)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	($1.65)	($1.57)	($1.61)
Q2 2018	3	($1.69)	($1.44)	($1.60)
Q3 2018	3	($2.14)	($1.42)	($1.76)
Q4 2018	3	($1.67)	($1.00)	($1.34)

Agios Pharmaceuticals (NASDAQ AGIO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/6/2018		($1.67)					N/A
5/4/2018	Q1 2018	($1.60)	($1.63)	$11.93 million	$8.80 million	View	N/A
2/14/2018	Q4 2017	($1.65)	($1.81)	$12.65 million	$9.80 million	View	Listen
11/1/2017	Q3 2017	($1.78)	($1.59)	$10.85 million	$11.35 million	View	N/A
8/8/2017	Q2 2017	($1.57)	($1.78)	$10.68 million	$11.30 million	View	Listen
5/4/2017	Q1 2017	($1.80)	($1.56)	$9.65 million	$10.51 million	View	Listen
2/16/2017	Q416	($1.51)	($1.34)	$10.89 million	$22.65 million	View	Listen
11/3/2016	Q316	($1.52)	($1.63)	$7.82 million	$8.98 million	View	Listen
8/4/2016	Q216	($0.48)	($1.47)	$39.62 million	$6.98 million	View	Listen
5/5/2016	Q116	($0.79)	($0.61)	$20.94 million	$31.30 million	View	Listen
2/18/2016	Q415	($0.27)	($1.08)	$28.78 million	$6.22 million	View	Listen
11/5/2015	Q315	($0.89)	($1.07)	$17.21 million	$5.80 million	View	Listen
8/6/2015	Q215	($0.46)	($0.85)	$25.75 million	$13.20 million	View	Listen
5/7/2015	Q115	($0.86)	($0.13)	$10.86 million	$34.20 million	View	Listen
2/17/2015	Q414	($0.55)	($0.76)	$10.94 million	$14.64 million	View	Listen
11/7/2014	Q314	($0.53)	$0.10	$8.45 million	$33.90 million	View	Listen
8/7/2014	Q2	($0.47)	($0.54)	$11.00 million	$8.41 million	View	Listen
5/8/2014	Q1	($0.37)	($0.39)	$7.19 million	$8.41 million	View	Listen
3/6/2014	Q4	($0.34)	($0.40)	$6.19 million	$6.70 million	View	Listen
11/7/2013		($0.28)	($0.47)	$6.22 million	$6.27 million	View	Listen
9/5/2013	Q2 2013	($0.28)	($2.80)	$6.19 million	$6.27 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

Agios Pharmaceuticals (NASDAQ:AGIO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Agios Pharmaceuticals (NASDAQ AGIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.02%
Institutional Ownership Percentage: 93.99%

Insider Trading History for Agios Pharmaceuticals (NASDAQ:AGIO)

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ AGIO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/7/2018	Scott Biller	Insider	Sell	3,000	$81.81	$245,430.00	2,881
5/1/2018	David P Schenkein	CEO	Sell	13,000	$83.04	$1,079,520.00	13,000
4/23/2018	Steven L Hoerter	Insider	Sell	2,050	$85.95	$176,197.50	2,050
4/12/2018	Christopher Bowden	Insider	Sell	2,000	$85.10	$170,200.00	2,881
4/5/2018	Scott Biller	Insider	Sell	3,000	$75.20	$225,600.00	60,196
4/2/2018	David P Schenkein	CEO	Sell	13,000	$77.72	$1,010,360.00
3/22/2018	Steven L Hoerter	Insider	Sell	2,050	$84.65	$173,532.50	2,050
3/19/2018	Kaye I Foster-Cheek	Director	Sell	6,800	$81.97	$557,396.00	9,000
3/16/2018	David Scadden	Director	Buy	200	$83.44	$16,688.00	571
3/5/2018	Scott Biller	Insider	Sell	3,000	$83.08	$249,240.00
3/1/2018	David P Schenkein	CEO	Sell	13,000	$81.09	$1,054,170.00
2/22/2018	Steven L Hoerter	Insider	Sell	2,050	$78.63	$161,191.50	2,050
2/16/2018	Christopher Bowden	Insider	Sell	2,000	$77.65	$155,300.00
2/5/2018	Scott Biller	Insider	Sell	3,000	$76.04	$228,120.00
2/1/2018	Christopher Bowden	Insider	Sell	2,000	$78.75	$157,500.00	2,881
2/1/2018	David P Schenkein	CEO	Sell	13,000	$78.75	$1,023,750.00	13,000
1/26/2018	David P Schenkein	CEO	Sell	23,572	$81.09	$1,911,453.48	23,572
1/24/2018	David P Schenkein	CEO	Sell	46,408	$80.01	$3,713,104.08	32,875
1/23/2018	Corp /De/ Celgene	Major Shareholder	Buy	851,154	$67.00	$57,027,318.00	1,374,599
1/23/2018	Steven L Hoerter	Insider	Sell	25,000	$74.83	$1,870,750.00	25,000
1/16/2018	David P Schenkein	CEO	Sell	53,000	$73.16	$3,877,480.00	53,000
1/12/2018	Carman Alenson	Insider	Sell	2,150	$75.00	$161,250.00	2,150
1/10/2018	Scott Biller	Insider	Sell	3,000	$65.00	$195,000.00	56,059
12/7/2017	Lewis Clayton Jr. Cantley	Director	Sell	3,838	$59.37	$227,862.06	80,851
12/1/2017	David P Schenkein	CEO	Sell	6,000	$61.55	$369,300.00	6,000
12/1/2017	Scott Biller	Insider	Sell	2,146	$60.79	$130,455.34	8,410
11/14/2017	Lewis Clayton Jr. Cantley	Director	Sell	4,000	$60.88	$243,520.00	82,394
11/1/2017	David P Schenkein	CEO	Sell	6,000	$63.85	$383,100.00
11/1/2017	Scott Biller	Insider	Sell	2,146	$62.69	$134,532.74
10/17/2017	Lewis Clayton Jr. Cantley	Director	Sell	4,000	$71.10	$284,400.00	84,394
10/16/2017	Lewis Clayton Jr. Cantley	Director	Sell	1,000	$71.09	$71,090.00	84,394
10/4/2017	David P Schenkein	CEO	Sell	80,000	$70.14	$5,611,200.00
10/4/2017	Scott Biller	Insider	Sell	10,470	$70.00	$732,900.00
10/2/2017	David P Schenkein	CEO	Sell	6,000	$66.76	$400,560.00
10/2/2017	Scott Biller	Insider	Sell	2,146	$67.23	$144,275.58
9/18/2017	David P Schenkein	CEO	Sell	35,000	$67.12	$2,349,200.00	35,000
9/14/2017	Lewis Clayton Jr. Cantley	Director	Sell	4,000	$65.59	$262,360.00	86,394
9/13/2017	Lewis Clayton Jr. Cantley	Director	Sell	1,000	$65.47	$65,470.00	86,394
9/11/2017	Scott Biller	Insider	Sell	15,000	$65.00	$975,000.00	6,264
9/1/2017	David P Schenkein	CEO	Sell	6,000	$62.20	$373,200.00	6,000
9/1/2017	Scott Biller	Insider	Sell	2,146	$61.99	$133,030.54	8,410
8/23/2017	Lewis Clayton Jr. Cantley	Director	Sell	4,000	$56.85	$227,400.00
8/2/2017	David P Schenkein	CEO	Sell	27,000	$59.95	$1,618,650.00	3,000
8/2/2017	Scott Biller	Insider	Sell	23,146	$59.60	$1,379,501.60	8,410
7/20/2017	Lewis Clayton Jr. Cantley	Director	Sell	9,000	$56.36	$507,240.00	86,697
7/19/2017	Lewis Clayton Jr. Cantley	Director	Sell	3,500	$56.14	$196,490.00	86,697
7/7/2017	Scott Biller	Insider	Sell	2,146	$55.00	$118,030.00	8,410
7/3/2017	David P Schenkein	CEO	Sell	3,000	$51.18	$153,540.00	3,000
6/21/2017	Scott Biller	Insider	Sell	4,292	$55.00	$236,060.00
6/14/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,000	$50.87	$101,740.00	90,197
6/7/2017	David P Schenkein	CEO	Sell	3,000	$50.02	$150,060.00	1,100
5/25/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,036	$47.10	$95,895.60	91,206
5/1/2017	David P Schenkein	CEO	Sell	3,000	$50.06	$150,180.00	3,000
4/24/2017	Celgene European Investment Co	Major Shareholder	Buy	624,575	$49.50	$30,916,462.50
4/18/2017	Lewis Clayton Jr. Cantley	Director	Sell	5,090	$54.37	$276,743.30	93,751
4/17/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,036	$55.24	$112,468.64	93,751
4/3/2017	David P Schenkein	CEO	Sell	3,000	$58.62	$175,860.00	3,000
4/3/2017	Scott Biller	Insider	Sell	2,146	$58.03	$124,532.38
3/23/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,036	$53.11	$108,131.96	94,769
3/20/2017	Scott Biller	Insider	Sell	6,438	$55.00	$354,090.00	21,403
3/6/2017	Robert Nelsen	Director	Sell	40,599	$50.84	$2,064,053.16	109,230
2/28/2017	Robert Nelsen	Director	Sell	243,082	$49.36	$11,998,527.52	109,230
2/23/2017	Robert Nelsen	Director	Sell	135,364	$49.37	$6,682,920.68	73,078
2/16/2017	David P Schenkein	CEO	Sell	6,000	$50.01	$300,060.00	6,000
10/27/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$48.94	$122,545.76	108,405
10/5/2016	Scott Biller	Insider	Sell	5,000	$55.00	$275,000.00	48,270
9/28/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$54.00	$33,858.00	109,659
9/27/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$54.15	$33,952.05	109,659
9/20/2016	Scott Biller	Insider	Sell	5,000	$50.00	$250,000.00	48,270
8/30/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$36.81	$23,079.87	110,913
8/29/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$37.81	$23,706.87	110,913
7/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$42.80	$107,171.20	112,167
7/25/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$41.85	$26,239.95	112,167
6/28/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$41.88	$104,867.52	125,921
6/27/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$40.37	$25,311.99	125,921
6/8/2016	Scott Biller	Insider	Sell	27,500	$65.00	$1,787,500.00	81,376
5/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$51.69	$129,431.76	127,175
4/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$53.44	$133,813.76	128,429
4/25/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$55.00	$34,485.00	128,429
3/30/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$37.19	$93,123.76	129,683
2/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$37.90	$94,901.60	131,086
1/29/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$42.93	$107,496.72	131,713
12/29/2015	Lewis Clayton Jr. Cantley	Director	Sell	10,664	$64.93	$692,413.52	132,967
12/15/2015	John Duncan Higgons	COO	Sell	20,000	$50.09	$1,001,800.00	61,835
11/17/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,408	$59.83	$562,880.64	138,299
11/16/2015	John Duncan Higgons	COO	Sell	20,000	$61.51	$1,230,200.00	81,835
11/2/2015	Scott Biller	insider	Sell	5,500	$77.12	$424,160.00	34,070
10/23/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$61.16	$593,496.64	143,002
10/15/2015	John Duncan Higgons	COO	Sell	20,000	$71.04	$1,420,800.00	81,835
9/30/2015	Scott Biller	insider	Sell	5,500	$70.44	$387,420.00	34,070
9/25/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$83.25	$807,858.00	147,854
9/24/2015	Glenn Goddard	SVP	Sell	6,000	$85.97	$515,820.00
9/15/2015	John Duncan Higgons	COO	Sell	20,000	$91.11	$1,822,200.00	141,835
8/18/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$94.94	$921,297.76
8/17/2015	John Duncan Higgons	COO	Sell	20,000	$92.24	$1,844,800.00	131,835
7/23/2015	Glenn Goddard	SVP	Sell	7,000	$120.45	$843,150.00
7/20/2015	Scott Biller	Insider	Sell	5,500	$113.87	$626,285.00
7/17/2015	Glenn Goddard	SVP	Sell	13,000	$113.71	$1,478,230.00
7/16/2015	John Duncan Higgons	COO	Sell	20,000	$114.02	$2,280,400.00
7/16/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$114.28	$1,108,973.12
6/25/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$105.13	$1,020,181.52
6/15/2015	John Duncan Higgons	COO	Sell	7,000	$105.23	$736,610.00
6/8/2015	Scott Biller	Insider	Sell	5,500	$121.85	$670,175.00
6/1/2015	Christopher Bowden	Insider	Sell	5,000	$120.67	$603,350.00
6/1/2015	David P Schenkein	CEO	Sell	13,000	$120.67	$1,568,710.00
5/27/2015	David P Schenkein	CEO	Sell	8,929	$120.05	$1,071,926.45
5/27/2015	Glenn Goddard	SVP	Sell	2,171	$120.05	$260,628.55
5/20/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$116.64	$1,131,874.56
5/15/2015	John Duncan Higgons	COO	Sell	7,417	$112.89	$837,305.13
5/12/2015	David P Schenkein	CEO	Sell	5,200	$110.02	$572,104.00
5/8/2015	David P Schenkein	CEO	Sell	3,900	$101.32	$395,148.00
5/7/2015	Scott Biller	Insider	Sell	5,500	$96.32	$529,760.00
4/24/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$105.15	$1,020,375.60
4/15/2015	John Duncan Higgons	COO	Sell	6,583	$99.54	$655,271.82
4/13/2015	David P Schenkein	CEO	Sell	3,900	$100.03	$390,117.00
4/8/2015	Scott Biller	Insider	Sell	5,500	$97.64	$537,020.00
4/1/2015	David P Schenkein	CEO	Sell	3,900	$92.54	$360,906.00
3/27/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$93.58	$908,100.32
3/16/2015	Glenn Goddard	SVP	Sell	10,000	$106.24	$1,062,400.00
3/16/2015	John Duncan Higgons	COO	Sell	7,000	$106.24	$743,680.00
3/16/2015	Scott Biller	Insider	Sell	5,500	$106.81	$587,455.00
3/2/2015	David P Schenkein	CEO	Sell	7,800	$107.05	$834,990.00
2/13/2015	David P Schenkein	CEO	Sell	1,471	$120.22	$176,843.62
2/13/2015	Glenn Goddard	SVP	Sell	1,316	$120.31	$158,327.96
2/11/2015	Glenn Goddard	SVP	Sell	16,513	$107.12	$1,768,872.56
2/9/2015	Glenn Goddard	SVP	Sell	15,000	$105.81	$1,587,150.00
2/2/2015	David P Schenkein	CEO	Sell	10,400	$114.31	$1,188,824.00
1/2/2015	David P Schenkein	CEO	Sell	13,000	$110.08	$1,431,040.00
1/2/2015	John Duncan Higgons	COO	Sell	12,000	$110.08	$1,320,960.00
1/2/2015	Scott Biller	Insider	Sell	4,500	$110.08	$495,360.00
12/16/2014	Celgene European Investment Co	Major Shareholder	Buy	228,645	$110.75	$25,322,433.75
12/16/2014	John Maraganore	Director	Buy	1,806	$110.75	$200,014.50
12/1/2014	David P Schenkein	CEO	Sell	13,000	$97.03	$1,261,390.00
12/1/2014	John Duncan Higgons	COO	Sell	12,000	$97.03	$1,164,360.00
12/1/2014	Scott Biller	Insider	Sell	4,500	$97.03	$436,635.00
11/3/2014	Glenn Goddard	SVP	Sell	2,000	$81.71	$163,420.00
11/3/2014	John Duncan Higgons	COO	Sell	13,000	$81.71	$1,062,230.00
11/3/2014	Scott Biller	Insider	Sell	4,500	$81.71	$367,695.00
10/1/2014	Glenn Goddard	SVP	Sell	1,500	$60.07	$90,105.00
10/1/2014	John Duncan Higgons	COO	Sell	13,000	$60.07	$780,910.00
10/1/2014	Scott Biller	Insider	Sell	4,500	$60.07	$270,315.00
9/26/2014	David P Schenkein	CEO	Sell	60,000	$62.68	$3,760,800.00
9/26/2014	Glenn Goddard	SVP	Sell	17,500	$56.53	$989,275.00
9/19/2014	Scott Biller	Insider	Sell	37,996	$50.45	$1,916,898.20
9/2/2014	Glenn Goddard	SVP	Sell	10,000	$46.30	$463,000.00
9/2/2014	John Duncan Higgons	COO	Sell	13,000	$46.30	$601,900.00
9/2/2014	Scott Biller	Insider	Sell	4,500	$46.30	$208,350.00
8/26/2014	John Duncan Higgons	COO	Sell	5,000	$45.05	$225,250.00
8/11/2014	David P Schenkein	CEO	Sell	4,530	$40.17	$181,970.10
7/1/2014	David P Schenkein	CEO	Sell	13,000	$46.52	$604,760.00
7/1/2014	Glenn Goddard	SVP	Sell	3,500	$46.52	$162,820.00
7/1/2014	John Duncan Higgons	COO	Sell	12,000	$46.52	$558,240.00
7/1/2014	Scott Biller	Insider	Sell	4,500	$46.52	$209,340.00
6/23/2014	John Maraganore	Director	Buy	2,300	$43.98	$101,154.00
6/20/2014	Scott Biller	Insider	Sell	2,004	$50.05	$100,300.20
6/13/2014	John Duncan Higgons	COO	Sell	5,000	$45.27	$226,350.00
6/3/2014	John Duncan Higgons	COO	Sell	7,000	$34.47	$241,290.00
5/6/2014	John Duncan Higgons	COO	Sell	5,000	$45.73	$228,650.00	200,090
5/1/2014	Glenn Goddard	SVP	Sell	2,000	$42.39	$84,780.00
5/1/2014	John Duncan Higgons	COO	Sell	7,000	$42.39	$296,730.00	205,090
5/1/2014	Scott Biller	Insider	Sell	4,500	$42.39	$190,755.00	30,000
4/29/2014	Celgene European Investment Co	major shareholder	Buy	294,800	$44.00	$12,971,200.00
4/29/2014	John Maraganore	Director	Buy	2,250	$44.00	$99,000.00	46,583
4/7/2014	Glenn Goddard	SVP	Sell	2,000	$45.17	$90,340.00
4/7/2014	John Duncan Higgons	COO	Sell	3,000	$45.17	$135,510.00	209,090
4/1/2014	Glenn Goddard	SVP	Sell	4,000	$38.08	$152,320.00
4/1/2014	John Duncan Higgons	COO	Sell	12,000	$38.08	$456,960.00	209,090
4/1/2014	Scott Biller	Insider	Sell	4,500	$38.08	$171,360.00	30,000
3/7/2014	Glenn Goddard	SVP	Sell	17,468	$42.11	$735,577.48
3/7/2014	John Duncan Higgons	COO	Sell	14,646	$41.41	$606,490.86	109,090
3/3/2014	John Duncan Higgons	COO	Sell	8,000	$29.85	$238,800.00	109,090
3/3/2014	Scott Biller	Insider	Sell	6,000	$29.85	$179,100.00
2/10/2014	Glenn Goddard	SVP	Sell	6,000	$30.44	$182,640.00
1/27/2014	Glenn Goddard	SVP	Sell	7,000	$26.29	$184,030.00
1/21/2014	Glenn Goddard	SVP	Sell	10,000	$34.71	$347,100.00
7/29/2013	Celgene European Investment Co	Major Shareholder	Buy	708,333	$18.00	$12,749,994.00

(Data available from 1/1/2013 forward)

Agios Pharmaceuticals (NASDAQ AGIO) News Headlines

Source:

Date	Headline
	Agios (AGIO) Progressing Well on Pipeline Amid Competition finance.yahoo.com - May 24 at 5:43 PM
	Agios Pharmaceuticals (AGIO) Now Covered by Analysts at Citigroup www.americanbankingnews.com - May 23 at 12:45 PM
	Stock Traders Purchase Large Volume of Agios Pharmaceuticals Put Options (AGIO) www.americanbankingnews.com - May 23 at 6:58 AM
	Agios Pharmaceuticals (AGIO) Receives Average Recommendation of "Buy" from Brokerages www.americanbankingnews.com - May 20 at 11:33 AM
	3 Things In Biotech, May 18: Exelixis Digs Europe, GT Bio Wants A Shot, Agios Bags Another seekingalpha.com - May 19 at 8:09 AM
	Zacks: Brokerages Expect Agios Pharmaceuticals (AGIO) Will Announce Quarterly Sales of $13.02 Million www.americanbankingnews.com - May 18 at 2:16 AM
	Agios Pharmaceuticals (AGIO) Expected to Announce Earnings of -$1.66 Per Share www.americanbankingnews.com - May 16 at 7:12 PM
	Agios to Present New Clinical Data from its IDH Programs at ASCO finance.yahoo.com - May 16 at 5:45 PM
	SunTrust Banks Equities Analysts Cut Earnings Estimates for Agios Pharmaceuticals (AGIO) www.americanbankingnews.com - May 9 at 8:39 AM
	Q2 2018 EPS Estimates for Agios Pharmaceuticals (AGIO) Lowered by Oppenheimer www.americanbankingnews.com - May 9 at 8:39 AM
	Agios Pharmaceuticals (AGIO) Insider Scott Biller Sells 3,000 Shares www.americanbankingnews.com - May 8 at 7:58 PM
	Credit Suisse Group Reiterates $95.00 Price Target for Agios Pharmaceuticals (AGIO) www.americanbankingnews.com - May 8 at 2:28 PM
	Agios Pharmaceuticals to Post FY2021 Earnings of $6.10 Per Share, Oppenheimer Forecasts (AGIO) www.americanbankingnews.com - May 8 at 6:43 AM
	Agios Pharmaceuticals (AGIO) PT Raised to $115.00 www.americanbankingnews.com - May 7 at 2:56 PM
	Agios Pharma (AGIO) PT Raised to $90 at RBC Capital www.streetinsider.com - May 7 at 8:18 AM
	Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Investor Day 2018 Results - Earnings Call Transcript seekingalpha.com - May 6 at 8:22 AM
	Head to Head Contrast: Agios Pharmaceuticals (AGIO) & AMAG Pharmaceuticals (AMAG) www.americanbankingnews.com - May 4 at 6:15 PM
	Agios Provides Business Update on Discovery Research Strategy and Pipeline ... globenewswire.com - May 4 at 5:35 PM
	Agios Pharmaceuticals Q1 revenues off 16% seekingalpha.com - May 4 at 5:35 PM
	Agios (AGIO) Q1 Loss Wider than Expected; Sales Miss finance.yahoo.com - May 4 at 5:35 PM
	Agios Pharmaceuticals (AGIO) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS www.americanbankingnews.com - May 4 at 4:36 PM
	Agios Pharmaceuticals (AGIO) Upgraded at ValuEngine www.americanbankingnews.com - May 4 at 3:35 PM
	BRIEF-Agios Qtrly Loss Per Share $1.63 www.reuters.com - May 4 at 8:17 AM
	Agios Pharmaceuticals EPS in-line, misses on revenue seekingalpha.com - May 4 at 8:17 AM
	Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day finance.yahoo.com - May 4 at 8:17 AM
	Agios Pharmaceuticals: 1Q Earnings Snapshot finance.yahoo.com - May 4 at 8:17 AM
	Why Earnings Season Could Be Great for Agios (AGIO) www.nasdaq.com - May 3 at 5:26 PM
	Agios Pharmaceuticals (AGIO) CEO David P. Schenkein Sells 13,000 Shares www.americanbankingnews.com - May 3 at 4:32 PM
	$13.59 Million in Sales Expected for Agios Pharmaceuticals (AGIO) This Quarter www.americanbankingnews.com - May 1 at 4:10 AM
	Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings? finance.yahoo.com - April 30 at 5:15 PM
	Analysts Expect Agios Pharmaceuticals (AGIO) Will Post Earnings of -$1.60 Per Share www.americanbankingnews.com - April 29 at 7:58 AM
	Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results Webcast on Friday, May 4, 2018 finance.yahoo.com - April 27 at 8:28 AM
	Insider Selling: Agios Pharmaceuticals (AGIO) Insider Sells 2,050 Shares of Stock www.americanbankingnews.com - April 25 at 7:10 PM
	Agios Pharmaceuticals (AGIO) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - April 25 at 11:19 AM
	Agios Pharmaceuticals (AGIO) Scheduled to Post Earnings on Wednesday www.americanbankingnews.com - April 25 at 3:52 AM
	Biotech Stocks Face a Steep Drop www.investopedia.com - April 23 at 8:14 AM
	Heard in the halls of biotech: I’ll meet you in the Valium room. www.msn.com - April 21 at 8:18 AM
	Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline finance.yahoo.com - April 18 at 5:46 PM
	Cann Reaffirms "Hold" Rating for Agios Pharmaceuticals (AGIO) www.americanbankingnews.com - April 17 at 11:37 AM
	Christopher Bowden Sells 2,000 Shares of Agios Pharmaceuticals (AGIO) Stock www.americanbankingnews.com - April 16 at 4:27 PM
	Agios Pharmaceuticals' (AGIO) Hold Rating Reaffirmed at Janney Montgomery Scott www.americanbankingnews.com - April 14 at 10:05 AM
	Agios Pharmaceuticals (AGIO) Upgraded by Leerink Swann to "Outperform" www.americanbankingnews.com - April 14 at 10:05 AM
	Agios Pharmaceuticals (AGIO) Expected to Announce Earnings of -$1.60 Per Share www.americanbankingnews.com - April 12 at 9:07 AM
	Agios Pharmaceuticals (AGIO) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 11 at 10:42 PM
	Credit Suisse Group Reiterates "$95.00" Price Target for Agios Pharmaceuticals (AGIO) www.americanbankingnews.com - April 11 at 9:21 AM
	Needham & Company LLC Raises Agios Pharmaceuticals (AGIO) Price Target to $72.00 www.americanbankingnews.com - April 10 at 11:38 PM
	Scott Biller Sells 3,000 Shares of Agios Pharmaceuticals (AGIO) Stock www.americanbankingnews.com - April 9 at 7:19 PM
	Why Alcoa, Merck, and Agios Pharmaceuticals Jumped Today finance.yahoo.com - April 9 at 5:23 PM
	ASLAN Pharmaceuticals Files For $86 Million US IPO seekingalpha.com - April 7 at 8:22 AM
	David P. Schenkein Sells 13,000 Shares of Agios Pharmaceuticals (AGIO) Stock www.americanbankingnews.com - April 4 at 10:40 PM

Agios Pharmaceuticals (NASDAQ:AGIO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Agios Pharmaceuticals (NASDAQ:AGIO) Income Statement, Balance Sheet and Cash Flow Statement

Agios Pharmaceuticals (NASDAQ AGIO) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff